Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9854 | 0.94 | IDO1 (0.36) | MAPTGAAIDO1TDO2 | |
| SCHEMBL27115657 | 0.78 | IDO1 (0.32) | IDO1TDO2 | |
| SCHEMBL17194021 | 0.78 | IDO1 (0.32) | IDO1TDO2 | |
| SCHEMBL27115656 | 0.78 | IDO1 (0.32) | IDO1TDO2 | |
| SCHEMBL3384150 | 0.78 | MAPT (0.44) | MAPTGAAIDO1TDO2 | |
| SCHEMBL27115719 | 0.75 | TDP1 (0.32) | IDO1TDO2 | |
| SCHEMBL22881094 | 0.75 | APLNR (0.33) | — | |
| SCHEMBL19309633 | 0.74 | — | — | |
| SCHEMBL1564309 | 0.72 | PDK1 (0.30) | — | |
| SCHEMBL8352236 | 0.72 | IDO1 (0.36) | MAPTGAAIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852163-A | Macrocyclic compound containing heteroatoms, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| EP-1870409-B1 | BENZIMIDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-1870409-B1 | BENZIMIDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-05-12 | — | — | EP | disclosed |
| US-7425634-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| EP-1870409-A1 | BENZIMIDAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-12-26 | — | — | EP | disclosed |
| EP-1870409-A1 | BENZIMIDAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-5373004-A | Cyclopentane ring introduced into side chain; administering for treatment of osteoporosis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1994-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | RORC, RORB, RORA | MAPT 1809/4885GAA 2685/4885IDO1 1451/4885 |
| US-20070010542-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | MAPT 4733/4885GAA 186/4885IDO1 1234/4885 |
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | NR5A1, AR, SRD5A1 | MAPT 3317/4885GAA 4658/4885IDO1 552/4885 |
| US-20070015782-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | MAPT 4733/4885GAA 186/4885IDO1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.